News

Shares of Regeneron Pharmaceuticals, Inc. REGN have lost 22.6% year to date against the industry’s growth of 0.6%. The stock ...
Intellia Therapeutics plunged 29% on safety concerns but rebounded as the full story emerged, showing the value of patience.
Ligand Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 80 to 84.
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...